Metabolism And Health Effects Of Citrus Limonoids in Hypercholesterolemic Humans
Primary Purpose
Hypercholesterolemia
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Citrus Limonoid Beverage
Placebo beverage
Sponsored by
About this trial
This is an interventional basic science trial for Hypercholesterolemia focused on measuring hypercholesterolemia, inflammation, citrus limonoids
Eligibility Criteria
Inclusion Criteria:
- Hypercholesterolemic, total blood cholesterol 200-300 mg/dL
- BMI 20-35 kg/m2
- normal Complete Blood Count
- normal serum transaminases, alkaline phosphatase, and creatinine
- normal thyroid function
- LDL cholesterol > 130 mg/dL
- Triglyceride < 300 mg/dL
- serum C-Reactive Protein 1.0-25 mg/L
Exclusion Criteria:
- current pregnancy or lactation
- smoking
- use of alcohol > 1 drink per day (1 oz distilled liquor, 3 oz wine, 12 oz beer)
- reported history of cardiovascular disease or chronic inflammatory diseases
- current users of oral contraceptives
- lipid-lowering, anti-inflammatory, anti-coagulant, or thyroid medications
- currently drinking more than 4 glasses per day of orange or grapefruit juice
Sites / Locations
- USDA Western Human Nutrition Research Center
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Group1
Group 2
Arm Description
Group 1 consumes Placebo beverage for 56 days followed by Citrus Limonoid Beverage for 56 days.
Group 2 consumes Citrus Limonoid Beverage for 56 days followed by Placebo beverages for 56 days
Outcomes
Primary Outcome Measures
Change in plasma lipids
Plasma cholesterol, LDL-cholesterol, HDL-cholesterol, triglyceride (TG), and remnant chylomicron particle concentrations will be determined. Lipid particle sizing will be performed by using nuclear magnetic resonance (NMR) technology. Plasma concentrations of apoproteins A1, B, C-III, and E will be measured.
Secondary Outcome Measures
Change in liver and renal function
Serum sodium, potassium, chloride, carbon dioxide, urea nitrogen, creatinine, glucose, calcium, protein, albumin, alkaline phosphatase, asparagine transaminase (AST), bilirubin, alanine transaminase (ALT), and lactate dehydrogenase (LDH) were performed at the Pathology Laboratory of the University of California Davis Medical Center to assess liver and renal function.
Full Information
NCT ID
NCT02011789
First Posted
December 4, 2013
Last Updated
December 9, 2013
Sponsor
USDA, Western Human Nutrition Research Center
Collaborators
The Beverage Institute for Health & Wellness, United States Department of Agriculture (USDA)
1. Study Identification
Unique Protocol Identification Number
NCT02011789
Brief Title
Metabolism And Health Effects Of Citrus Limonoids in Hypercholesterolemic Humans
Official Title
A Pilot Study To Determine The Metabolism And Health Effects Of Citrus Limonoids in Hypercholesterolemic Human Subjects
Study Type
Interventional
2. Study Status
Record Verification Date
December 2013
Overall Recruitment Status
Completed
Study Start Date
April 2007 (undefined)
Primary Completion Date
July 2010 (Actual)
Study Completion Date
July 2010 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
USDA, Western Human Nutrition Research Center
Collaborators
The Beverage Institute for Health & Wellness, United States Department of Agriculture (USDA)
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Limonoids are compounds found in citrus juices, seeds and peel. Some research shows that they reduce blood cholesterol and also reduce the incidence of several forms of cancer. Although these compounds are part of the natural human diet, the dose required to provide health benefits and the risks associated with the intake of high doses by humans have not been studied. This study will examine metabolism, safety, lipid-lowering and anti-inflammatory effects of limonoids. The dose of limonoids in this study is equivalent to that found in six 8 oz glasses of orange juice per day. The investigators hypothesize that limonin glucoside supplementation will reduce total cholesterol, LDL cholesterol, ratio of LDL and HDL cholesterol, number of LDL particles, and serum markers of inflammation.
Detailed Description
This is a 127-day study with a cross-over design, divided into three metabolic periods (P1, P2, and P3). For the first 14 days (P1), all subjects will receive two placebo beverages and will be asked to consume one each with breakfast and dinner. Then in metabolic period 2 (P2), subjects will be randomly assigned to one of two groups (Group 1 and Group 2). For the next 56 days, Group 1 will continue to consume two placebo beverages per day, while Group 2 will consume two beverages containing limonoids (250 mg/beverage). During the final 56 days (P3), the beverages provided to Group 1 will contain limonoids, and beverages provided to Group 2 will be placebo. Both the placebo and limonoid beverages will be 12-oz buffered, sterile, orange flavored, artificially sweetened beverage, containing 60 mg vitamin C, 11 mg riboflavin and zero calories. Subjects are instructed that they must drink all the beverage provided each day. Beverages will contain a biomarker (riboflavin), and the biomarker is assayed in urine samples collected every 2 weeks at the beverage pickup appointments to monitor compliance. The subjects will be informed that they are being monitored for compliance. Limonin glucoside is obtained from citrus waste materials utilizing chromatographic methods that employ food grade approved media and solvents. The final pure limonin glucoside is fractionally crystallized from a concentrated water solution of a chromatographically purified extract. The crystalline material is separated from the mother liquor, dried and subjected to mass spectral and nuclear magnetic resonance assessment. The spectral data is compared to data acquired for a pure limonin glucoside standard to establish final purity which is better than 95%.
Blood samples (approximately 70 ml, less than five tablespoons) will be drawn after a 12 hour overnight fast on study days 1, 15, 71 and 127 by venipuncture. These blood samples will be used to determine serum limonoids, complete blood cell count (CBC), and comprehensive chemistry panel (CCP), serum lipids, markers of inflammation, lymphocyte and monocytes functions. In addition to the fasting blood draws on days 15 (Group 2) and day 71 (Group 1), repeated blood samples (5 ml each time, approximately one teaspoon) will be drawn at 2, 4, 6, 8, and 24 hr after taking two 12-oz limonoid beverages (total limonoids 500mg) to determine the absorption and metabolism of limonoids. The investigators note that the blood samples drawn 24-h after the limonoid intake will be on study day 16 for Group 2 and day 72 for Group 1. The total amount of blood drawn will be less than 500 ml (2 cups) in 127 days. A spot urine sample will be collected at the same visit as the fasting blood draws, and every two weeks at the beverage pickup appointments. Repeated blood draws at 0, 2, 4, 6, and 8 hr after the limonoid supplement will be accompanied by the collection of urine samples. No food will be allowed during the 8 hrs; water intake will be monitored and restricted to one liter. Subjects will be served two standardized meals during this time, each representing 35% of their daily caloric intake, one after the 0 hr blood draw and the other after the 8 hr blood draw.
Subjects will be instructed not to change their diets, exercise or lifestyle during the course of the study. They will also be instructed not to consume any citrus fruit/juice (orange, grape fruit) throughout the study. Three 24-hour dietary recalls will be collected by telephone during the last week of each metabolic period (P1, P2, P3). A standardized diet will be served for all three meals for each day prior to the blood draws.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypercholesterolemia
Keywords
hypercholesterolemia, inflammation, citrus limonoids
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
10 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Group1
Arm Type
Experimental
Arm Description
Group 1 consumes Placebo beverage for 56 days followed by Citrus Limonoid Beverage for 56 days.
Arm Title
Group 2
Arm Type
Active Comparator
Arm Description
Group 2 consumes Citrus Limonoid Beverage for 56 days followed by Placebo beverages for 56 days
Intervention Type
Dietary Supplement
Intervention Name(s)
Citrus Limonoid Beverage
Intervention Description
The limonoid containing beverage will be 12-oz buffered, sterile, orange flavored, artificially sweetened, containing 60 mg vitamin C, 11 mg riboflavin and 250 mg limonin glucoside.
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo beverage
Intervention Description
The placebo beverage will be 12-oz buffered, sterile, orange flavored, artificially sweetened, containing 60 mg vitamin C and 11 mg riboflavin.
Primary Outcome Measure Information:
Title
Change in plasma lipids
Description
Plasma cholesterol, LDL-cholesterol, HDL-cholesterol, triglyceride (TG), and remnant chylomicron particle concentrations will be determined. Lipid particle sizing will be performed by using nuclear magnetic resonance (NMR) technology. Plasma concentrations of apoproteins A1, B, C-III, and E will be measured.
Time Frame
1, 15, 71 and 127 days
Secondary Outcome Measure Information:
Title
Change in liver and renal function
Description
Serum sodium, potassium, chloride, carbon dioxide, urea nitrogen, creatinine, glucose, calcium, protein, albumin, alkaline phosphatase, asparagine transaminase (AST), bilirubin, alanine transaminase (ALT), and lactate dehydrogenase (LDH) were performed at the Pathology Laboratory of the University of California Davis Medical Center to assess liver and renal function.
Time Frame
1, 15, 71 and 127 days
Other Pre-specified Outcome Measures:
Title
Change in inflammatory markers
Description
Plasma concentrations of c-reactive protein (CRP), tumor necrosis factor (TNF-alpha), interleukin-1 (IL-1beta) and interleukin-6 (IL-6) will be determined.
Time Frame
1, 15, 71 and 127 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Hypercholesterolemic, total blood cholesterol 200-300 mg/dL
BMI 20-35 kg/m2
normal Complete Blood Count
normal serum transaminases, alkaline phosphatase, and creatinine
normal thyroid function
LDL cholesterol > 130 mg/dL
Triglyceride < 300 mg/dL
serum C-Reactive Protein 1.0-25 mg/L
Exclusion Criteria:
current pregnancy or lactation
smoking
use of alcohol > 1 drink per day (1 oz distilled liquor, 3 oz wine, 12 oz beer)
reported history of cardiovascular disease or chronic inflammatory diseases
current users of oral contraceptives
lipid-lowering, anti-inflammatory, anti-coagulant, or thyroid medications
currently drinking more than 4 glasses per day of orange or grapefruit juice
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Darshan S Kelley, PhD
Organizational Affiliation
USDA, Western Human Nutrition Research Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
USDA Western Human Nutrition Research Center
City
Davis
State/Province
California
ZIP/Postal Code
95616
Country
United States
12. IPD Sharing Statement
Links:
URL
http://www.ars.usda.gov/main/site_main.htm?modecode=53-06-25-00
Description
United States Department of Agriculture, Western Human Nutrition Research Center
Learn more about this trial
Metabolism And Health Effects Of Citrus Limonoids in Hypercholesterolemic Humans
We'll reach out to this number within 24 hrs